Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

Share Price is delayed by 15 minutes
Get Live Data
32.50    0.00 (0.00%)
Bid:
32.00
Ask:
33.00
Spread: 1.00 (3.125%)
Market Cap: £19.28m
KRM Live PriceLast checked at - London Stock Exchange

Intraday Krm22 Plc Share Chart

Loan Facility Amendment

23 Dec 2024 07:00

RNS Number : 0213R
KRM22 PLC
23 December 2024
 

KRM22 plc

("KRM22", the "Group" or the "Company")

Loan Facility Amendment

 

KRM22 plc, (AIM: KRM) the technology and software investment company that focuses on risk management for capital markets, announces that an interest repayment date has been deferred in relation to the Company's £5.0m convertible loan facility agreement (the "Facility"), entered into on 17 June 2023, with Trading Technologies International, Inc. ("TT"), the Company's largest shareholder, in which £4.5m has already been drawn down to date.

 

As announced in the Company's results for the year ended 31 December 2023, TT had provided the Company with a letter of support confirming that TT would be willing to enter into discussions with KRM22 around amending the terms of the Facility to ensure that KRM22 does not breach the cash covenant in the Facility. 

 

Under the terms of the original Facility, KRM22 has the ability to defer interest payments for the initial 18 months (the "Initial Interest Period"), with the total deferred interest in the Initial Interest Period being paid in two equal instalments on the calendar quarters ending on the 18th and 21st month anniversary of the Facility, this being 31 December 2024 and 31 March 2025 respectively. KRM22 and TT have agreed that the interest payment that was due on 31 December 2024 will now be due for payment on 31 March 2025.

 

The amendment of the Facility will allow the Company to conserve cash, ensuring greater financial flexibility and stability for ongoing operations and future initiatives while it continues to remain in active discussion with TT.

 

Detail of the amended terms of the Facility

 

The Terms of the original Facility were included in the Company's 'New Debt Facility' announcement which was released in June 2023. The Facility remains at a maximum of £5.0m which is secured on the Company's assets. Under the original Facility it states that interest accruing in the first 18 months after the date of the Original Loan Agreement be paid (i) fifty percent (50%) on the Quarter Date immediately following the 18-month anniversary of the date of the Original Loan Agreement (being 31 December 2024), and (ii) fifty percent (50%) on the Quarter Date immediately following the 21-month anniversary of the date of the Original Loan Agreement (being 31 March 2025) with the only amendment being the deferral of the first interest rate payment to align with the second one due on the 31 March 2025. The interest rate and the covenants remain as originally agreed.

 

Related Party Transaction

 

TT is considered a "related party" as defined under the AIM Rules as a result of its substantial shareholding of 24.8 per cent. in the Company. The deferral of the interest repayment date by TT and the amendment of the Facility constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules.

 

The Independent Directors, being Kim Suter, Dan Carter, Garry Jones, Sandy Broderick and Steve Sparke, consider, having consulted with the Company's nominated adviser for the purposes of the AIM Rules, Cavendish, that the amended terms of the Facility are fair and reasonable insofar as the Company's shareholders are concerned.

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

For further information please contact:

 

KRM22 plc

Garry Jones, Chairman

Dan Carter, CEO

Kim Suter, CFO

 

InvestorRelations@krm22.com

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Carl Holmes / Rory Sale (Corporate Finance)

Sunila de Silva (ECM)

 

+44 (0)20 7220 0500

 

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

 

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' trading and corporate risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimise risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 plc is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at KRM22.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQKDBQKBDDDBB
Date   Source Headline
26th May 20263:24 pmRNSHolding(s) in Company
26th May 20262:25 pmRNSHolding(s) in Company
22nd May 20267:00 amRNSDirector Dealings
20th May 202611:19 amRNSDirector Dealings
20th May 20267:00 amRNSNotice of AGM and Posting of Annual Report
13th May 20267:00 amRNSFinal Results
29th Jan 20267:00 amRNSTrading Update
7th Jan 20267:00 amRNSAppointment of Director
20th Nov 20254:12 pmRNSTR-1
11th Nov 20257:00 amRNSIssue of Equity
10th Nov 20259:28 amRNSHolding(s) in Company
5th Nov 20251:05 pmRNSResult of GM
15th Oct 20257:00 amRNSResult of Placing
14th Oct 20254:50 pmRNSProposed Placing and Subscription
17th Sep 20257:00 amRNSInterim Results
7th Aug 20257:00 amRNSTrading Update
21st Jul 20257:00 amRNSIssue of Equity
27th Jun 20252:10 pmRNSResult of AGM
6th Jun 20257:00 amRNSDirector Dealing
2nd Jun 20257:00 amRNSIssue of Restricted Stock Units
30th May 20257:00 amRNSNotice of AGM and Posting of Annual Report
21st May 20257:00 amRNSDirector Dealing
19th May 20257:00 amRNSFinal Results
29th Apr 20257:00 amRNSFacility Amendment
7th Apr 20257:00 amRNSNew Customer Contracts
1st Apr 20257:00 amRNSFacility Amendment
18th Mar 20257:00 amRNSIssue of Equity
4th Mar 20257:00 amRNSNew Customer Contract
13th Feb 20255:00 pmRNSDirector Dealing
22nd Jan 20257:00 amRNSTrading Update
10th Jan 20257:00 amRNSIssue of Equity
23rd Dec 20247:00 amRNSLoan Facility Amendment
15th Oct 20247:00 amRNSIssue of Equity
25th Sep 20247:00 amRNSInterim Results
3rd Sep 20247:00 amRNSChange of Registered Office
29th Aug 20247:00 amRNSNew Customer Contract
22nd Aug 202410:00 amRNSGrant of Options and Director/PDMR Shareholding
19th Aug 20247:00 amRNSIssue of Equity
18th Jul 20247:00 amRNSHalf Year Trading Update
21st Jun 202412:49 pmRNSResult of AGM
29th May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSDirector Dealings
15th Apr 20247:00 amRNSNew Customer Contract
10th Apr 20247:00 amRNSIssue of Equity
7th Mar 20247:00 amRNSBoard Changes
21st Feb 20247:00 amRNSTrading Update
1st Dec 20237:00 amRNSIssue of Restricted Stock Units
26th Sep 20237:00 amRNSInterim Results
27th Jul 202311:48 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.